Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
84.3 EUR | +1.93% | +6.10% | +40.03% |
Apr. 02 | Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment | MT |
Mar. 12 | Rovi, Partners to Form Entity for Advanced Therapies R&D | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+40.03% | 4.59B | |
+34.00% | 664B | |
+29.29% | 567B | |
-7.75% | 354B | |
+18.53% | 330B | |
+4.95% | 286B | |
+13.79% | 234B | |
+4.93% | 199B | |
-9.78% | 196B | |
-4.89% | 148B |
- Stock Market
- Equities
- ROVI Stock
- News Laboratorios Farmaceuticos Rovi, S.A.
- Transcript : Laboratorios Farmaceuticos Rovi, S.A., 2023 Earnings Call, Feb 27, 2024